Investors in the U.S. only watch Japanese giant Takeda Pharmaceutical because they see it as competition.
Outside the U.S., Fusilev is being marketed by Pfizer (PFE), Sanofi-Aventis (SNY), and Takeda Pharmaceutical (TKPHI) in Japan.
FORBES: Straightforward Talk From Spectrum Pharmaceuticals Helps Attract Investors
Mutual, which is owned by Takeda Pharmaceutical, points to a 2011 Supreme Court ruling called Pliva v.
FORBES: Good For Generic Drugmakers? White House To Argue In Favor Of Preemption
All told, these trials involved 3, 725 patients who had received Pargluva, placebo, or Actos, another diabetes drug made by Takeda Pharmaceutical.
But Januvia isn't just a newer version of existing diabetes blockbusters like Avandia, from GlaxoSmithKline, and Actos, from Japan's Takeda Pharmaceutical .
The study could open new avenues for treating heart disease, aside from being a marketing coup for Japan's Takeda Pharmaceutical, which makes Actos.
In the past several months, studies of Actos and Avandia, from Takeda Pharmaceutical and GlaxoSmithKline, have failed to alleviate safety concerns with those drugs.
Consider some of the Japanese names not appearing on this Fabulous 50: Sony, Honda, Canon, Sharp, Aeon, NTT, NEC, Toshiba, Fujitso, Takeda Pharmaceutical, Fuji Photo Film, Nomura, Seven-Eleven, Mitsubishi and Mitsui.
But Januvia isn't just a newer version of existing diabetes blockbusters like Avandia, from GlaxoSmithKline (nyse: GSK - news - people ), and Actos, from Japan's Takeda Pharmaceutical .
Pfizer (PFE), Sanofi Aventis (SNY) and Takeda Pharmaceutical (TKPHI) markets Fusilev outside the U.S. With them already involved with Spectrum and amply knowledgable about its products, they are the one most likely to pursue Spectrum, if it were willing to sell.
FORBES: Spectrum Pharmaceuticals Gets Lift from FDA Action On One Of Its Cancer Treatments
Actos, from Japanese pharmaceutical giant Takeda, is the only other drug in the same class as Avandia.
In an age when only giants are supposed to survive in the pharmaceutical world, little Takeda thrives, showing record profits and record sales for 11 consecutive years.
Nissen is doing a study of Actos for Takeda and consults for most major pharmaceutical firms, but he gives all the fees drug makers send him to charity.
应用推荐